ClinicalTrials.gg
CompletedNCT01004224Updated Oct 4, 2019

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

A Phase 1 interventional study of BGJ398 in Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification and Bladder Cancer With FGFR3 Mutation or Fusion, sponsored by Novartis Pharmaceuticals. Completed at 50 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Lung Neoplasms by Novartis — 2 open to participants now, 5 under way, none of them phase 3. Lung Neoplasms · Novartis.

Enrollment
12th of 36
208 · median 95
Started
2009
the only one that year
Phase 1
11 of 40
none open now
Registered
12th of 40
by date

Among the 40 studies in Lung Neoplasms by Novartis, this one is the 12th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2009, is one of 11 in phase 1, and was the 12th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 40 studies in Lung Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lung Neoplasms by Novartis, or all of them as a file.
02

Study summary

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

03

Conditions studied

  • Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
  • Squamous Lung Cancer With FGFR1 Amplification
  • Bladder Cancer With FGFR3 Mutation or Fusion
  • Advanced Solid Tumors With FGFR1 Amplication
  • Advanced Solid Tumors With FGFR2 Amplication
  • Advanced Solid Tumors With FGFR3 Mutation

Keywords

  • advanced solid tumors
  • lung cancer
  • bladder cancer
  • BGJ398
  • FGFR
  • kinase inhibitor
  • advanced solid malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologically/ confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 mutation, for which no further effective standard anticancer treatment exists
  • Adequate bone marrow function
  • Adequate hepatic and renal function
  • Adequate cardiovascular function
  • .

    • For women: Must be surgically sterile, , or compliant with a medically approved contraceptive regimen during and for 3 months after the treatment period; must have a negative serum or urine pregnancy test and must not be nursing.
    • For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 3 months after the treatment period

Exclusion criteria

Exclusion Criteria:

  • Patients with primary CNS tumor or CNS tumor involvement
  • Patients with history and/or current evidence of endocrine alteration of calcium-phosphate homeostasis
  • History and/or current evidence of ectopic mineralization/ calcification including but not limited to the soft tissue, kidneys, intestine, myocard and lung with the exception of calcified lymphnodes and asymptomatic coronary calcification
  • Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/ band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis etc., confirmed by ophthalmologic examination.
  • History or current evidence of cardiac arrhythmia and/or conduction abnormality
  • Women who are pregnant or nursing.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    BGJ398

    Drug: BGJ398

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)

    Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD). This will be calculated using an established statistical model, based on incidence of adverse events and serious adverse events, physical examinations, vital signs, electrocardiograms, and laboratory parameters

    Time frame: 23 months

Secondary outcomes

  1. To assess preliminary anti-tumor activity of BGJ398 for patients in expansion Arm 4 (previously treated patients with advanced/metastatic UCC with FGFR3 gene alterations)

    overall response rate (ORR), as assessed by investigator per RECIST v 1.0; overall survival (OS), duration of response (DOR) and disease control rate (DCR) will be assessed

    Time frame: 23 months

  2. To determine the pharmacokinetic (PK) profiles of oral BGJ398

    Time vs. concentration profiles, PK parameters of BGJ398 and known active metabolite(s).

    Time frame: 23 months

  3. To evaluate the pharmacodynamic effect of the drug.

    Pre- vs. post treatment serial changes in FGF23 plasma levels (not done for patients enrolled to expansion Arm 4)

    Time frame: 23 months

  4. Assess preliminary anti-tumor activity for patients not in Arm 4.

    Overall tumor response rate (ORR) and PFS assessed by investigator per RECIST

    Time frame: 23 months

07

Study locations

50 sites
  • Novartis Investigative Site
    Duarte, California 91010 3000, United States
  • Novartis Investigative Site
    Los Angeles, California 90033, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • University of Colorado Dept. of Anschutz Cancer (3)
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    New Haven, Connecticut 06520, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering Cancer Center Onc. Dept..
    New York, New York 10021, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Columbus, Ohio 43221, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital Onc Dept
    Philadelphia, Pennsylvania 19107-5098, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15232, United States
  • Novartis Investigative Site
    Memphis, Tennessee 38120, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84103, United States
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Vienna, A-1100, Austria
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Montpellier Cedex 5, 34298, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Saint-Herblain Cédex, 44805, France
  • Novartis Investigative Site
    Suresnes, 92150, France
  • Novartis Investigative Site
    Toulouse Cedex 9, 31059, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Meldola, FC 47014, Italy
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1066 CX, Netherlands
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Singapore, 169610, Singapore
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46009, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Madrid, 28050, Spain
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Izmir, 35040, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2009 to primary completion in Oct 2018, 105 months.

Of 128 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's 105 months is above that.

Counting every sponsor, half of 291 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2009
First posted
Oct 29, 2009
StartActual
Dec 11, 2009
Primary completionActual
Oct 8, 2018
CompletionActual
Oct 8, 2018
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01004224
Responsible party
Sponsor
First posted
Oct 29, 2009
Start date
Dec 11, 2009
Primary completion
Oct 8, 2018
Completion
Oct 8, 2018
Last update
Oct 4, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion